Clinical Trials · NCT06164873
A Study of IBI362 9 mg in Chinese Adults With Obesity
- Phase
- Phase 3
- Recruitment status
- Unknown
- Sponsor
- Innovent Biologics (Suzhou) Co. Ltd.
- Enrollment
- 462
- Start date
- Dec 2023
- Locations
- 1 site, China
- Primary endpoint
- Percent Change from Baseline in Body Weight